Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 12/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.42 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27033726 | 0.88 | CHRM1 (0.43) | KMT2ACHRM1CDK2CCNE1CCNA2 | |
| SCHEMBL24477559 | 0.86 | KMT2A (0.57) | KMT2AMEN1TDP1LMNAALDH1A1 | |
| SCHEMBL30839140 | 0.83 | CHRM1 (0.42) | KMT2ACHRM1CDK2CCNE1CCNA2 | |
| SCHEMBL24482006 | 0.82 | CDK2 (0.48) | KMT2ACHRM1CDK2CCNE1CCNA2 | |
| SCHEMBL34467975 | 0.80 | CHRM1 (0.45) | KMT2ACHRM1CDK2CCNE1CCNA2 | |
| SCHEMBL17339938 | 0.80 | POLB (0.56) | KMT2AMEN1LMNAALDH1A1HTT | |
| SCHEMBL29763021 | 0.80 | KMT2A (0.64) | KMT2ACHRM1MEN1TDP1LMNA | |
| SCHEMBL26790449 | 0.80 | KMT2A (0.46) | KMT2ACHRM1CDK2CCNE1CCND1 | |
| SCHEMBL30817612 | 0.80 | KMT2A (0.40) | KMT2ACDK2CCNE1CCNA2CCND1 | |
| SCHEMBL27213310 | 0.79 | CHRM1 (0.44) | KMT2ACHRM1CDK2CCNE1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-120051470-A | Azaquinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240166635-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc | 2024-05-23 | — | — | US | disclosed |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4251613-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116528869-A | Amino heteroaryl kinase inhibitors | 安锐生物医药科技(广州)有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | KMT2A 174/4885CHRM1 2188/4885CDK2 7/4885 |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | KMT2A 414/4885CHRM1 4279/4885CDK2 4/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | KMT2A 709/4885CHRM1 4/4885CDK2 1208/4885 |
| US-20240166635-A1 | AMINOHETEROARYL KINASE INHIBITORS | CDK2, CDK3, CDKL1 | KMT2A 602/4885CHRM1 4804/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.